StreetInsider.com News Articles

AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 2.7% Yield

Thu, 10 Sep 2026 14:19:25 -0400

AbbVie (NYSE: ABBV) declared a quarterly dividend of $1.73 per share, or $6.92 annualized.

The dividend will be payable on November 16, 2026, to stockholders of record on October 15, 2026, with an ex-dividend date of October 14, 2026.

The annual yield on the dividend is 2.7 percent.

For a dividend history and other dividend-related data on AbbVie (ABBV) click here.

AbbVie Declares Quarterly Dividend

Thu, 10 Sep 2026 14:17:00 -0400

NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.

The cash dividend is payable November 16, 2026, to stockholders of record at the close of business on October 15, 2026.

Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About

AbbVie Declares Quarterly Dividend

Thu, 10 Sep 2026 14:17:00 -0400

NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.

The cash dividend is payable November 16, 2026, to stockholders of record at the close of business on October 15, 2026.
Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About

AbbVie atogepant meets all endpoints in menstrual migraine Phase 3 trial

Thu, 10 Sep 2026 08:55:19 -0400

AbbVie (NYSE: ABBV) announced positive topline results from its Phase 3 LUNA study evaluating atogepant for the preventive treatment of menstrual migraine in adults, according to a company press release.

The study enrolled 468 adult female participants with pure menstrual migraine or menstrually-related migraine across sites in Europe and Asia. Participants took atogepant for seven consecutive days starting three days before the onset of menses, over three menstrual cycles.

Atogepant met the primary endpoint, showing a reduction of 1.20 migraine days during the perimenstrual period compared with 0.40 days for placebo, a difference of 0.80 fewer migraine days versus placebo (p<0.0001). The

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

Thu, 10 Sep 2026 08:55:00 -0400

Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability^2,4
Atogepant demonstrated statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked secondary endpoints versus placebo in the Phase 3 LUNA study (p<0.0001)¹
No treatment options are currently approved for menstrual migraine, underscoring the urgent need for care approaches specifically designed for this patient population^2,5
NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

Thu, 10 Sep 2026 08:55:00 -0400

Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability^2,4
Atogepant demonstrated statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked secondary endpoints versus placebo in the Phase 3 LUNA study (p<0.0001)¹
No treatment options are currently approved for menstrual migraine, underscoring the urgent need for care approaches specifically designed for this patient population^2,5
NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from

Abbvie (ABBV) PT Raised to $315 at HSBC

Thu, 10 Sep 2026 03:28:30 -0400
HSBC analyst Rajesh Kumar raised the price target on Abbvie (NYSE: ABBV) to $315.00 (from $300.00) while maintaining a Buy rating.

Abbvie (ABBV) PT Raised to $282 at BofA Securities

Tue, 08 Sep 2026 05:50:37 -0400

BofA Securities analyst Tim Anderson raised the price target on Abbvie (NYSE: ABBV) to $282.00 (from $276.00) while maintaining a Buy rating.
The analyst comments "Post-Apogee deal close, we update our estimates to incorporate zumilokibart (zumi) and raise our PO to $282 from $276. The higher PO reflects a move to a 20x forward P/E from 19.5x, consistent with the recent sector re-rating and the addition of zumi offers better visibility to sales outlook when Skyrizi LOE’s (2033-35E). We model ~$7.5bn nominal and ~$5bn risk-adj. peak AD sales for zumi, driven by growth in the advanced- therapy AD market and a

Abbvie (ABBV) PT Raised to $282 at BofA Securities

Tue, 08 Sep 2026 05:50:37 -0400

BofA Securities analyst Tim Anderson raised the price target on Abbvie (NYSE: ABBV) to $282.00 (from $276.00) while maintaining a Buy rating.
The analyst comments "Post-Apogee deal close, we update our estimates to incorporate zumilokibart (zumi) and raise our PO to $282 from $276. The higher PO reflects a move to a 20x forward P/E from 19.5x, consistent with the recent sector re-rating and the addition of zumi offers better visibility to sales outlook when Skyrizi LOE’s (2033-35E). We model ~$7.5bn nominal and ~$5bn risk-adj. peak AD sales for zumi, driven by growth in the advanced- therapy AD market and a

AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial

Thu, 03 Sep 2026 09:15:18 -0400

AbbVie (NYSE: ABBV) reported that its investigational drug etentamig met dual primary endpoints in the Phase 3 CERVINO trial, showing improved response rates and progression-free survival compared with standard available therapies in patients with relapsed or refractory multiple myeloma.

The trial enrolled 393 patients who had received a median of three prior lines of therapy. At a median follow-up of 11.4 months, etentamig produced an objective response rate of 74.0% versus 45.7% for standard therapies. The drug also reduced the risk of disease progression or death by 60% compared with standard therapies, with a hazard ratio of 0.40.

Twelve-month overall survival was

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi

Thu, 03 Sep 2026 09:15:00 -0400

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus investigator's choice of standard available therapies
Etentamig demonstrated low rates of cytokine release syndrome (CRS) and fatal infections with monthly dosing (Q4W) from initiation following a single step-up dose
Etentamig's dosing schedule and clinical profile may offer a differentiated treatment option for patients and providers
Results support the potential of etentamig, a second-generation BCMA-directed T-cell engager, to enable treatment across a range of settings, including outpatient and community-based care

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi

Thu, 03 Sep 2026 09:15:00 -0400

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus investigator's choice of standard available therapies
Etentamig demonstrated low rates of cytokine release syndrome (CRS) and fatal infections with monthly dosing (Q4W) from initiation following a single step-up dose
Etentamig's dosing schedule and clinical profile may offer a differentiated treatment option for patients and providers
Results support the potential of etentamig, a second-generation BCMA-directed T-cell engager, to enable treatment across a range of settings, including outpatient and community-based care

Form 8-K AbbVie Inc. For: Sep 03

Thu, 03 Sep 2026 08:48:00 -0400
si-local-file:///var/storage/secattach/20260903/27022603.html

AbbVie completes $10.9B acquisition of Apogee Therapeutics

Thu, 03 Sep 2026 08:35:16 -0400

AbbVie (NYSE: ABBV) has completed its acquisition of Apogee Therapeutics (NASDAQ: APGE), paying $135.11 per share in cash for a total equity value of approximately $10.9 billion, according to a company statement.

Apogee's common stock ceased trading on the Nasdaq stock exchange prior to market open on Sept. 3, 2026.

The acquisition adds Apogee's pipeline of antibodies targeting inflammatory pathways to AbbVie's immunology portfolio. Apogee's lead asset, zumilokibart, is a monoclonal antibody targeting IL-13 in development for atopic dermatitis. In a Phase 2 clinical trial, approximately two-thirds of patients on treatment achieved significant skin clearance at 16 weeks. Longer-term data from the

AbbVie completes $10.9B acquisition of Apogee Therapeutics

Thu, 03 Sep 2026 08:35:16 -0400

AbbVie (NYSE: ABBV) has completed its acquisition of Apogee Therapeutics (NASDAQ: APGE), paying $135.11 per share in cash for a total equity value of approximately $10.9 billion, according to a company statement.

Apogee's common stock ceased trading on the Nasdaq stock exchange prior to market open on Sept. 3, 2026.

The acquisition adds Apogee's pipeline of antibodies targeting inflammatory pathways to AbbVie's immunology portfolio. Apogee's lead asset, zumilokibart, is a monoclonal antibody targeting IL-13 in development for atopic dermatitis. In a Phase 2 clinical trial, approximately two-thirds of patients on treatment achieved significant skin clearance at 16 weeks. Longer-term data from the

AbbVie Completes Acquisition of Apogee Therapeutics

Thu, 03 Sep 2026 08:34:00 -0400

Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases
Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis
Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma
AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88
NORTH CHICAGO, Ill., Sept. 3, 2026

AbbVie Completes Acquisition of Apogee Therapeutics

Thu, 03 Sep 2026 08:34:00 -0400

Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases
Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis
Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma
AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88
NORTH CHICAGO, Ill., Sept. 3, 2026

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Thu, 03 Sep 2026 08:05:00 -0400

NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will participate in a fireside chat at 9:00 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Thu, 03 Sep 2026 08:05:00 -0400

NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will participate in a fireside chat at 9:00 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and

Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care

Wed, 02 Sep 2026 08:00:00 -0400

Building on insights from the U.S. Aesthetics Evolution series, including What Consumers Really Want, new global report explores evolving consumer attitudes toward beauty and aesthetic treatments
NORTH CHICAGO, Ill., Sept. 2, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today unveiled the Layered Beauty: The New Aesthetic Mindset report, informed by research among more than 12,000 beauty-involved consumers across nine global markets, complemented by practitioner expertise and regional perspectives. The report provides a global perspective on the impact of cultural attitudes toward beauty and aging to evolve the aesthetic treatment

Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care

Wed, 02 Sep 2026 08:00:00 -0400

Building on insights from the U.S. Aesthetics Evolution series, including What Consumers Really Want, new global report explores evolving consumer attitudes toward beauty and aesthetic treatments
NORTH CHICAGO, Ill., Sept. 2, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today unveiled the Layered Beauty: The New Aesthetic Mindset report, informed by research among more than 12,000 beauty-involved consumers across nine global markets, complemented by practitioner expertise and regional perspectives. The report provides a global perspective on the impact of cultural attitudes toward beauty and aging to evolve the aesthetic treatment

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

Tue, 01 Sep 2026 08:05:00 -0400

In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks¹
SkinMedica^® also introduces HA^5® Hydra Collagen Facial Mist for easy, on-the-go hydration
IRVINE, Calif., Sept. 1, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier Calming Cream. The restorative moisturizer is designed to soothe skin while helping restore and fortify the delicate skin barrier.

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

Tue, 01 Sep 2026 08:05:00 -0400

In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks¹
SkinMedica^® also introduces HA^5® Hydra Collagen Facial Mist for easy, on-the-go hydration
IRVINE, Calif., Sept. 1, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier Calming Cream. The restorative moisturizer is designed to soothe skin while helping restore and fortify the delicate skin barrier.

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

Mon, 31 Aug 2026 08:00:00 -0400

NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will participate in a fireside chat at 9:15 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

Mon, 31 Aug 2026 08:00:00 -0400

NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will participate in a fireside chat at 9:15 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the